Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
Published Online: 2015-05-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Allen Lee Cohn•Axel Grothey•David C Portnoy•Eric Van Cutsem•Federico Nasroulah•Gyorgy Bodoky•Jana Prausová•Josep Tabernero•Kentaro Yamazaki•Lorinda Simms•Philip R Clingan•Pilar Garcia-Alfonso•Radka Obermannova•Rocio Garcia-Carbonero•Sara Lonardi•Shao-Chun Chang•Tae Won Kim•Takayuki Yoshino•Tudor-Eliade Ciuleanu
